INTC vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Intel Corporation and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
Intel Corporation · Technology
$68.50
-13.9% upside to fair value
High Conviction
Grade D
VS
Johnson & Johnson · Healthcare
$238.46
-11.8% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
JNJ has more upside to fair value
(-11.8%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
JNJ |
| Current Price |
$68.50 |
$238.46 |
| Fair Value Estimate |
$59.00 |
$210.28 |
| Upside to Fair Value |
-13.9%
|
-11.8%
|
| Market Cap |
$343.9B |
$574.7B |
| Forward P/E |
-1245.8x
|
20.2x
|
| EV / EBITDA |
—
|
13.3x
|
| Price / Sales |
6.5x
|
6.2x
|
| Price / FCF |
-69.5x
|
29.4x
|
| Revenue Growth YoY |
+0.2%
|
+6.1%
|
| Gross Margin |
34.8%
|
72.8%
|
| Operating Margin |
-4.2%
|
27.2%
|
| Return on Equity |
-0.3%
|
32.87%
|
| Dividend Yield |
— |
2.18% |
| FCF Yield |
—
|
3.4%
|
| Analyst Consensus |
Hold
|
Moderate Buy
|
Investment Thesis
Intel is a legacy semiconductor leader attempting an ambitious turnaround under new CEO Lip-Bu Tan, pivoting from a pure-play chipmaker to an integrated device manufacturer (IDM 2.0) with foundry ambitions. The business remains structurally challenged: PC market share is eroding, foundry execution is unproven, negative free cash flow persists, and margins are compressed. However, the stock trades…
Johnson & Johnson is a high-quality healthcare conglomerate focused exclusively on Innovative Medicine and MedTech following the Kenvue spin-off. The company delivered $94.2B in FY2025 revenue with 6% operational growth, generated $19.7B in free cash flow, and guided for $99.5-100.5B in 2026 operational sales (above consensus). However, at $238 the stock trades at a P/S of 6.15x, well above the 5…
Accumulation Zones
| Metric |
INTC |
JNJ |
| Zone Low |
$44.00 |
$157.71 |
| Zone High |
$50.00 |
$178.74 |
| In Buy Zone? |
No
|
No
|